BEIJING, Dec. 31 /PRNewswire-FirstCall/ - This is a joint press release of Hiru Corporation (HIRU) and Hard to Treat Diseases (HTDS) - The two companies are pleased to announce the finalization and completion of the purchase and sale of the MindUp BioResearch Division. Details of the transaction completed on cash and stock basis can be found at the Pink Sheets web site www.pinksheets.com under the "filings" tab.

The buyer Hiru focuses on production and manufacturing of premium herbs, herbal extracts and herbal preparations. The company markets its herbal curatives across the Chinese market. The company's modern production and distribution methods hoisted the company's nation-wide reputation. The company became the leading private enterprise in agricultural industrialization in Chinese Jiangxi Province and earned the China national Good Manufacturing Practice & Implementation certificates.

In other news and events of Hiru, the company continues to seek other merger candidates. The company is seeking to reach the $100 million dollar revenue mark in the next 24 to 36 months. Hiru, a well developed China based company with a solid client base, currently enjoys gross revenues of (for the 11 months ended November 30, 2009) $27.3 million with a net profit of $4.795 million.

HTDS is a holdco of a China based Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Mellow Hope is the biggest exporter of Biological Vaccines in China. Other controlling interests include an East European (Serbian) medical company, Slavica Biochem whose experts are performing cutting edge research in the field of neurological impairments in Multiple Sclerosis (MS) and Traumatic Brain Injury (TBI).

In other news and events of HTDS, the company has completed its preliminary Q4 results. The financial numbers and comparisons will shortly be released by the company. The company is pleased with the preliminary financial results. As previously announced contracts, and revenues commence they are beginning to show up on the company books. The company has already started with its 1st phase of the stem cell bank development and intends to post its plan of action as filings with Pink Sheets shortly. The plan will include new laboratory, offices, equipment and the launch date.

Details of Hiru business activities can be found at this web site http://www.hirucorporation.com and Hard To treat Diseases at http://www.htdsmedical.com

To receive future updates, via email including quarterly newsletters and company updates which may not be newsworthy however important to the reader and followers of the company please sign up today free at www.minamargroup.com/updates

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc and HIRU Corporation that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc and HIRU Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc and HIRU Corporation is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc and HIRU Corporation's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc and HIRU Corporation's control. In addition to those discussed in Hard to Treat Diseases Inc and HIRU Corporation's press releases, public filings, and statements by Hard to Treat Diseases Inc and HIRU Corporation's management, including, but not limited to, Hard to Treat Diseases Inc and HIRU Corporation's estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc and HIRU Corporation's ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc and HIRU Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc and HIRU Corporation's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc and HIRU Corporation does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For any investor relations matters, please contact www.minamargroup.net/helpdesk; Investor Relations Department Inquiry, http://www.minamargroup.net/ (IR); For (M&A) and Corporate Matters, http://www.minamargroup.com

SOURCE Hard to Treat Diseases

Back to top